Cipralex in Treatment of Depressive Symptoms and Chronic Back Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2012-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Chronic low back pain (CLBP) is one of the most frequent forms of chronic pain and can result in significant functional impairment. This is often associated with major depression too. Previous research reported significant beneficial effects of antidepressant medication in alleviating depression and pain intensity. The aim of this study is to evaluate the efficacy of Escitalopram, a new kind of Selective Serotonin Reuptake Inhibitor (SSRI) in patients with CLBP in a prospective, randomized and double-blind clinical trial. The main hypothesis is:

-in comparison to placebo, subjects with CLBP and Cipralex report a significant reduction in depressive symptoms (\>= 50% of HAMD questionnaire) after 4 weeks of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Antidepressants on Back Pain

NCT00018200

Back Pain Sciatica

COMPLETED PHASE2

Efficacy of Antidepressants in Chronic Back Pain

NCT00964886

Back Pain

COMPLETED PHASE2

Neuroimaging Predictors of Antidepressant Treatment Outcome

NCT02000726

Depression

WITHDRAWN PHASE2

Study of Naltrexone-Induced Blockade of Antidepressant Effects

NCT04322526

Depression Major Depressive Disorder

COMPLETED PHASE4

Predictors of Antidepressant Response

NCT02178696

Depression

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pain is an unpleasant sensory and emotional experience. Chronic pain, including chronic low back pain, represents a major public health problem. Risk factors of chronicity of low back pain include high levels of psychological distress prior to or during the episode, premorbid association with work status or employment dissatisfaction, unemployment, poor self-rated health and low levels of physical activity. Other psychosocial features are poor social and educational status, previous sexual or physical abuse. Furthermore, mechanical strain on the spine from heavy lifting, repetitive lifting, twisting and vibration, including driving increase the risk. Static work postures, prolonged standing or walking, road traffic accidents and falls are also significantly related.While there is little evidence for a specific personality profile, stress, distress, anxiety, mood disorders and depression were consistently related to neck and back pain.

CLBP is associated with significant disability, functional impairment, high rates of psychiatric symptoms including anxiety and depression, and loss of other physical roles. These may produce social and functional problems, which include reduced earning capacity, unemployment and family disharmony. Chronic pain is also associated with loss of self confidence and self-esteem, leading to social withdrawal and social isolation. Men with CLBP have significantly higher lifetime rates of major depression, alcohol use disorder and major anxiety disorder. After age of pain onset, CLBP subjects had over 9 times the risk of developing major depression.

Depression is believed to be mediated by 5-HT and norepinephrine through the raphe nucleus and locus coeruleus projections to the cerebral cortex and forebrain limbic systems, whereas pain is believed to be mediated in part through descending 5-HT and norepinephrine pain pathways that provide inhibitory input to the dorsal horn neurons in the spinal cord. Global deficiences in 5-HT or norepinephrine neurotransmission would be predicted to affect both mood and pain thresholds, possibly accounting for the hgh comorbidity of painful symptoms in patients with depression.Accordingly, enhancement of both neurotransmitter or 5-HT alone would be expected both to improve symptoms of depression and to normalize pain thresholds.

In antidepressant treatment of CLBP, only 2 studies were published using SSRIs. One reported significantly higher pain intensity reduction in maprotilin group compared to paroxetine and placebo. The other showed no effect of paroxetine on depression or pain. Patients on SSRI, however, reduced the amount of analgesic medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Low Back Pain Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A, 2, II

Placebo 10mg per day for the first week, then 20mg per day till the end of study.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo 10mg per day for the first week, then 20mg per day till the end of study.

A, 1

Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.

Group Type EXPERIMENTAL

Escitalopram

Intervention Type DRUG

Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Escitalopram

Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.

Intervention Type DRUG

Placebo

Placebo 10mg per day for the first week, then 20mg per day till the end of study.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cipralex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* In- and out-patients at KH Bethanien, Greifswald, presenting with non-specific chronic low back pain lasting longer than 6 months (assessed with VAS and OLBPQ rev.)
* Age from 18 to 65 years
* Depressive symptoms (HAMD scores \>10)
* Significant disability in daily living tasks (Owestry Disability Index \>30%)
* Medication with nonsteroidal anti-inflammatory drugs.

Exclusion Criteria

* Other significant Axis I disorders, including psychosis, eating disorders, substance use disorders or recent suicidal behavior.
* Systemic inflammatory disorder, malignancy, other acute medical or neurological disorders, recent surgery within 12 months.
* Medication with opioids, corticosteroids, other psychotropic medication except Temazepam.
* History of gastric ulcer, gastritis or gastric bleeding.
* Known allergy or intolerance to Citalopram or Cipralex.
* Pregnant or lactating women.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No